Dr. Joel Kremer, founder and Chief Medical Officer of the United States Corrona Registry, visited Toronto this Wednesday October 13th to present his research and meet with the OBRI team.
Corrona is one of the largest chronic disease registries in the world with more than 40,000 Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PA) patients enrolled, and over 90,000 patient-years of data. Corrona was founded in 2000 to advance medical research and improve quality of care for patients living with chronic disease, and includes clinical registries for RA, PA, Spondyloarthritis (SpA) and Psoriasis.
Data for Corrona is collected from physicians and patients during routine medical visits in sites across the United States and some international countries and is used to monitor the safety and effectiveness of pharmaceutical treatments for a range of chronic diseases, including RA, SpA, and PA, among others. Corrona is an independent registry free from ownership or links to the pharmaceutical industry, and is run by a group of experienced researchers and clinical physicians across the United States.
While in Toronto, Dr. Kremer delivered two presentations – the first on the “Comparative effectiveness of biologic agents” at the University of Toronto Rheumatology Division rounds at Sick Kids Hospital, and the second on “Lipid effects of new biologic and small molecule interventions,” at Mount Sinai Hospital Rheumatology rounds. In addition to his role at Corrona, Dr. Kremer is a Professor of Medicine at Albany Medical College in Albany NY, Director of Research at The Center for Rheumatology.
We enjoyed discussing research trends, registry logistics, and future directions in arthritis research with Dr. Kremer and look forward to exploring research questions between our cohorts in the future.
For more information on Corrona, please visit their website: http://www.corrona.org/ or http://www.corronaresearchfoundation.org/.